CardioComm Solutions, Inc. (TSXV: EKG) has announced a collaboration with CancerCare Manitoba to launch an approximately one-year pilot study evaluating remote electrocardiogram monitoring for QT/QTc interval prolongation in breast cancer patients receiving selected drug therapies. The pilot will deploy CardioComm's HeartCheck™ CardiBeat handheld ECG monitor alongside a customised smartphone application, GEMS™ Mobile CCMB, supported by the company's SMART Monitoring ECG Service platform. Investors may be watching the announcement as a potential validation of CardioComm's remote cardiac monitoring technology within oncology care settings.

Key Points

  • CardioComm Solutions, Inc. (TSXV: EKG) is a Toronto-based healthcare technology company focused on cardiac remote patient monitoring solutions.
  • The company has launched a pilot collaboration with CancerCare Manitoba to evaluate home-based QT/QTc interval ECG monitoring for breast cancer patients on select drug therapies.
  • The pilot runs for approximately one year; financial terms and any associated revenue were not disclosed in the announcement.
  • Investors may be watching how patient adoption rates and clinical workflow outcomes shape potential future oncology applications for CardioComm's platform.

HeartCheck™ CardiBeat and GEMS™ Mobile CCMB Form Core of the Pilot Technology Stack

During the pilot, participating breast cancer patients will use CardioComm's HeartCheck™ CardiBeat handheld ECG monitor to record scheduled home ECGs and additional readings when cardiac symptoms such as dizziness, palpitations, or faintness occur. Recordings transfer via Bluetooth to GEMS™ Mobile CCMB, a customised smartphone application available through mobile app stores upon patient enrolment. CardioComm's GEMS™ Rhythm technology then analyses recordings for suspected QT/QTc prolongation, with reports securely transmitted to the designated CancerCare Manitoba care team through the SMART Monitoring Service platform.

QT/QTc Prolongation Risk Drives Clinical Rationale for Remote Cardiac Surveillance in Oncology

Certain cancer medications are known to prolong the QT/QTc interval, raising the risk of torsades de pointes — a potentially life-threatening abnormal heart rhythm that can cause dizziness, fainting, or in severe cases cardiac arrest. The release states that QT/QTc changes can develop between hospital ECG visits or go unrecognised when repeat appointments are delayed. Where the CCMB care team identifies material interval changes, treating physicians will assess whether medication adjustment, discontinuation, or an alternative therapy is required, with all clinical interpretation and treatment decisions remaining the responsibility of the care team.

Integration with CancerCare Manitoba's Noona Platform Supports End-to-End Patient Management

GEMS™ Mobile CCMB also facilitates entry of QT/QTc measurements into CCMB's MyCare Noona platform, which supports secure care-team communications, symptom tracking, questionnaires, appointments, and laboratory results. Together, the three components — GEMS™ Mobile CCMB, the SMART Monitoring Service, and Noona — are intended to create an integrated workflow connecting at-home ECG acquisition through to clinical follow-up. The pilot will assess patient adoption, automated monitoring workflows, and the potential reduction of avoidable hospital visits, with possible future applications across broader oncology care noted by the company.